drugset / Trial / NCT02231632
The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)
Phase 2/3
Completed
1200 enrolled
Institute of Medical Biology, Chinese Academy of Medical Sciences
Guangxi Center for Disease Control and Prevention · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this Phase 2/3 trial is to assess the safety and immunogenicity of Live attenuated Poliomyelitis vaccine (human diploid cell)
Timeline
- Start
- 2011-01
- Primary completion
- 2012-03
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Live attenuated Poliomyelitis vaccine (Human Diploid Cell) | Vaccine | 0.1 ml | Oral |
| Subject | Live attenuated Poliomyelitis vaccine (Human Diploid Cell) | Vaccine | 6.15 unknown | Oral |
| Subject | Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell) | Vaccine | 0.1 ml | Oral |
| Subject | Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell) | Vaccine | 6.15 unknown | Oral |